Novavax Inc Asset Resilience Ratio
Novavax Inc asset resilience ratio. Novavax Inc (NVAX) has an Asset Resilience Ratio of 55.24% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See NVAX defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Novavax Inc (2006–2025)
Asset resilience ratio of Novavax Inc from 2006 to 2025. This chart shows how Novavax Inc's Asset Resilience Ratio has changed over time. Read total liabilities of Novavax Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Novavax Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Novavax Inc (NVAX) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $527.88 Million | 55.24% |
| Total Liquid Assets | $527.88 Million | 55.24% |
Asset Resilience Insights
- Very High Liquidity: Novavax Inc maintains exceptional liquid asset reserves at 55.24% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Novavax Inc Industry Peers by Asset Resilience Ratio
Compare Novavax Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Novavax Inc Asset Resilience Ratio by Year (2006–2025)
Novavax Inc asset resilience ratio by year from 2006 to 2025. The table below shows the annual Asset Resilience Ratio data for Novavax Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 42.03% | $494.45 Million | $1.18 Billion | +16.85pp |
| 2024-12-31 | 25.18% | $392.89 Million | $1.56 Billion | +24.60pp |
| 2023-12-31 | 0.58% | $10.42 Million | $1.80 Billion | -- |
| 2021-12-31 | 0.00% | $0.00 | $2.58 Billion | -- |
| 2020-12-31 | 9.96% | $157.65 Million | $1.58 Billion | -- |
| 2019-12-31 | 0.00% | $0.00 | $172.96 Million | -- |
| 2018-12-31 | 10.57% | $21.98 Million | $207.98 Million | -6.29pp |
| 2017-12-31 | 16.86% | $51.00 Million | $302.49 Million | -6.25pp |
| 2016-12-31 | 23.11% | $91.13 Million | $394.30 Million | -12.52pp |
| 2015-12-31 | 35.63% | $137.55 Million | $386.04 Million | -13.54pp |
| 2014-12-31 | 49.17% | $135.72 Million | $276.00 Million | +43.41pp |
| 2013-12-31 | 5.76% | $13.60 Million | $235.94 Million | -20.34pp |
| 2012-12-31 | 26.10% | $26.71 Million | $102.34 Million | +19.78pp |
| 2011-12-31 | 6.32% | $4.21 Million | $66.58 Million | -25.24pp |
| 2010-12-31 | 31.55% | $23.61 Million | $74.84 Million | +26.65pp |
| 2009-12-31 | 4.90% | $4.19 Million | $85.61 Million | -4.19pp |
| 2008-12-31 | 9.09% | $6.96 Million | $76.62 Million | -37.07pp |
| 2007-12-31 | 46.16% | $42.14 Million | $91.29 Million | -8.35pp |
| 2006-12-31 | 54.51% | $66.43 Million | $121.88 Million | -- |
About Novavax Inc
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Com… Read more